Patient Assistance Programs for Ketamine Therapy

Patient assistance programs for ketamine therapy can lower treatment costs across three delivery formats: FDA-approved esketamine nasal spray (Spravato)in-office IV ketamine infusions, and compounded oral ketamine tablets. The strongest manufacturer discounts apply to Spravato, since it's the only ketamine-based medication with FDA approval and a brand-name copay program. Compounded ketamine tablets, which most Ketamine Tablet readers are prescribed, don't qualify for manufacturer coupons because no compounded formulation carries FDA approval. Instead, patients on compounded tablets typically rely on non-profit foundations, sliding-scale clinics, cash-pay pharmacy discounts, and HSA or FSA funds to bring down the cost of a monthly supply.

The Spravato Passport is Janssen Pharmaceuticals' copay assistance program for patients prescribed Spravato (esketamine), the only ketamine-derived medication with FDA approval for treatment-resistant depression. Commercially insured patients whose plan already covers Spravato can use the Passport program to reduce out-of-pocket costs to as little as $10 per treatment session, and there's no income requirement for the copay card itself. Annual benefit limits apply, so confirm current terms through your Spravato.com account or clinic before assuming full coverage. For broader coverage strategies, see our guide to the insurance coverage gap for oral ketamine tablets.

To enroll, ask your REMS-certified treatment setting whether it participates in the Passport program. A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-required safety program that restricts how certain high-risk drugs, including Spravato, can be prescribed, dispensed, and monitored. Once you enroll online or through your clinic, you'll receive a Passport program identifier that the clinic applies at each treatment session.

Patients who are uninsured or whose plan excludes Spravato coverage may qualify for Janssen CarePath, a manufacturer-run program that provides Spravato at no cost or reduced cost based on financial need. According to Janssen CarePath, eligibility is generally available to patients earning up to 400% of the federal poverty level, though program terms can change. Applying requires proof of income and documentation of insurance status; you can reach CarePath at 1-844-4SPRAVO (1-844-477-2860).

Compounded ketamine tablets are prepared by a licensed pharmacy for an individual patient rather than manufactured and approved by the FDA as a finished drug product. Because no company holds FDA approval for an oral ketamine tablet, there's no branded copay card or manufacturer free-drug program tied to it the way there is for Spravato. See our guide to compounded ketamine tablets for more on how compounding affects cost and quality. Patients prescribed compounded tablets need to combine several smaller savings strategies instead, outlined below.

Several non-profits help patients offset mental health treatment costs even when they don't run ketamine-specific programs.

• NAMI (National Alliance on Mental Illness), a grassroots mental health advocacy organization, operates a HelpLine (1-800-950-NAMI) that connects callers to state pharmaceutical assistance programs, charitable pharmacies, and appeals support for insurance denials.
• Mental Health America's local and state affiliates sometimes maintain emergency funds or connections to reduced-cost clinical services; contact your regional affiliate directly.
• The Patient Advocate Foundation, a national non-profit that provides free case management for patients navigating insurance and financial barriers, runs a Co-Pay Relief Program for specific diagnoses along with a general financial hardship fund and insurance appeals support.
• RxAssist and NeedyMeds maintain searchable databases of manufacturer and disease-specific assistance programs. Ketamine-specific listings are limited, but both are useful for locating help with concurrent medications.

Some telehealth ketamine platforms bundle prescriber and pharmacy costs into a single price that runs lower than paying for each separately, which can make them one of the more accessible entry points for uninsured patients. See our telehealth ketamine tablets guide for platform-specific pricing details.

State Pharmaceutical Assistance Programs (SPAPs) help specific populations, often Medicare beneficiaries or low-income residents, pay for medications beyond what Medicaid covers. Availability and covered drugs vary by state, so contact your state department of health or aging services directly.

Community Mental Health Centers (CMHCs), federally funded clinics that provide mental health services on a sliding fee scale based on income, don't commonly offer ketamine therapy yet, but centers with integrated medication management may prescribe it for appropriate patients at reduced cost.

Federally Qualified Health Centers (FQHCs), which serve underserved communities and qualify for the 340B Drug Pricing Program, may be able to offer lower-cost compounded ketamine tablets if a participating provider prescribes them. The Health Resources and Services Administration (HRSA) administers 340B, a federal program that lets qualifying health centers purchase outpatient drugs at reduced prices.

For treatment in hospital-based outpatient settings, ask the facility's financial counselor about charity care or financial assistance programs, which can reduce or eliminate clinical fees and, in some cases, drug administration costs, based on income verification.

Academic medical centers running ketamine research studies sometimes provide treatment at reduced or no cost to participants. Search ClinicalTrials.gov, the federal registry of clinical studies, for active ketamine trials matching your condition and location.

Patients frustrated by cost barriers can support broader change by working with mental health advocacy groups such as NAMI, documenting insurance denials and appeal outcomes, and contacting state and federal legislators about mental health parity enforcement. The Mental Health Parity and Addiction Equity Act requires many health plans to cover mental health treatment on par with medical and surgical care, though enforcement gaps remain a common source of ketamine coverage denials in practice.